Norges Bank
BCRX icon

Norges Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

Norges Bank’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-111,152
Closed -$996K – 187
2025
Q2 		$996K Sell
111,152
-176,806
-61% -$1.65M ﹤0.01% 1545
2025
Q1 		$2.16M Sell
287,958
-236,846
-45% -$1.91M ﹤0.01% 1514
2024
Q4 		$3.95M Sell
524,804
-87,096
-14% -$661K ﹤0.01% 1552
2024
Q3 		$4.65M Sell
611,900
-39,735
-6% -$302K ﹤0.01% 1537
2024
Q2 		$4.03M Sell
651,635
-354,394
-35% -$1.96M ﹤0.01% 1602
2024
Q1 		$5.11M Sell
1,006,029
-1,210,583
-55% -$6.81M ﹤0.01% 1613
2023
Q4 		$13.3M Buy
2,216,612
+1,370,000
+162% +$7.94M ﹤0.01% 1397
2023
Q3 		$5.99M Hold
846,612
– – ﹤0.01% 1642
2023
Q2 		$5.96M Sell
846,612
-38,251
-4% -$307K ﹤0.01% 1673
2023
Q1 		$7.38M Sell
884,863
-267,253
-23% -$2.57M ﹤0.01% 1667
2022
Q4 		$13.2M Buy
1,152,116
+79,000
+7% +$985K ﹤0.01% 1461
2022
Q3 		$13.5M Sell
1,073,116
-912,249
-46% -$11.7M ﹤0.01% 1414
2022
Q2 		$21M Buy
1,985,365
+1,189,837
+150% +$12.3M 0.01% 1213
2022
Q1 		$12.9M Buy
795,528
+77,854
+11% +$1.25M ﹤0.01% 1607
2021
Q4 		$9.94M Sell
717,674
-79,000
-10% -$1.05M ﹤0.01% 1760
2021
Q3 		$11.4M Buy
796,674
+625,323
+365% +$9.86M ﹤0.01% 1722
2021
Q2 		$2.71M Hold
171,351
– – ﹤0.01% 1978
2021
Q1 		$1.74M Sell
171,351
-179,409
-51% -$1.85M ﹤0.01% 2005
2020
Q4 		$2.61M Sell
350,760
-681,333
-66% -$3.51M ﹤0.01% 1928
2020
Q3 		$3.54M Buy
1,032,093
+488,600
+90% +$2.09M ﹤0.01% 1913
2020
Q2 		$2.59M Buy
+543,493
New +$2.17M ﹤0.01% 1938

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's BCRX Position: Q3 2025 in Review

Norges Bank sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 111,152 shares — an estimated $996K sold.

Norges Bank first reported a position in BCRX in Q2 2020 and held it in 21 quarters. The position peaked at $21M in Q2 2022. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Norges Bank reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 111,152 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $996K.
  • Norges Bank first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 21 quarters.
  • Norges Bank's BioCryst Pharmaceuticals position peaked at $21M in Q2 2022.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.